Kornitzer Capital Management Inc Bristol Myers Squibb CO Transaction History

Kornitzer Capital Management Inc

$5.21 Billion
Q3 2024

A detailed history of Kornitzer Capital Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Kornitzer Capital Management Inc holds 291,387 shares of BMY stock, worth $16.4 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

291,387

Previous 290,347 0.36%

Holding current value

$16.4 Million

Previous $12.1 Million 25.05%

% of portfolio

0.29%

Previous 0.24%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$39.66 - $51.75 $41,246 - $53,820	1,040 Added 0.36%	291,387 $15.1 Million
Q2 2024 Aug 02, 2024	BUY	$40.25 - $52.99 $352,912 - $464,616	8,768 Added 3.11%	290,347 $12.1 Million
Q1 2024 May 01, 2024	BUY	$47.98 - $54.4 $644,659 - $730,918	13,436 Added 5.01%	281,579 $15.3 Million
Q4 2023 Jan 31, 2024	BUY	$48.48 - $57.85 $188,296 - $224,689	3,884 Added 1.47%	268,143 $13.8 Million
Q3 2023 Oct 31, 2023	SELL	$57.89 - $64.73 $18,235 - $20,389	-315 Reduced 0.12%	264,259 $15.3 Million
Q2 2023 Aug 01, 2023	BUY	$63.71 - $70.74 $509 - $565	8 Added 0.0%	264,574 $16.9 Million
Q1 2023 May 09, 2023	SELL	$65.71 - $74.53 $11,039 - $12,521	-168 Reduced 0.06%	264,566 $18.3 Million
Q4 2022 Feb 02, 2023	SELL	$68.48 - $81.09 $154,764 - $183,263	-2,260 Reduced 0.85%	264,734 $19 Million
Q3 2022 Nov 03, 2022	SELL	$0.13 - $76.84 $546 - $323,112	-4,205 Reduced 1.55%	266,994 $19 Million
Q2 2022 Aug 03, 2022	SELL	$72.62 - $79.98 $248,505 - $273,691	-3,422 Reduced 1.25%	271,199 $20.9 Million
Q1 2022 Apr 27, 2022	SELL	$61.48 - $73.72 $61,172 - $73,351	-995 Reduced 0.36%	274,621 $20.1 Million
Q4 2021 Feb 01, 2022	BUY	$53.63 - $62.52 $221,062 - $257,707	4,122 Added 1.52%	275,616 $17.2 Million
Q3 2021 Nov 03, 2021	SELL	$59.17 - $69.31 $155,972 - $182,701	-2,636 Reduced 0.96%	271,494 $16.1 Million
Q2 2021 Jul 30, 2021	SELL	$61.91 - $67.42 $250,735 - $273,051	-4,050 Reduced 1.46%	274,130 $18.3 Million
Q1 2021 Apr 30, 2021	BUY	$59.34 - $66.74 $1.21 Million - $1.37 Million	20,455 Added 7.94%	278,180 $17.6 Million
Q4 2020 Jan 29, 2021	SELL	$57.74 - $65.43 $833,765 - $944,809	-14,440 Reduced 5.31%	257,725 $16 Million
Q3 2020 Oct 30, 2020	SELL	$57.43 - $63.64 $71,213 - $78,913	-1,240 Reduced 0.45%	272,165 $16.4 Million
Q2 2020 Aug 03, 2020	SELL	$54.82 - $64.09 $159,252 - $186,181	-2,905 Reduced 1.05%	273,405 $16.1 Million
Q1 2020 Apr 30, 2020	SELL	$46.4 - $67.43 $396,024 - $575,515	-8,535 Reduced 3.0%	276,310 $15.4 Million
Q4 2019 Jan 31, 2020	SELL	$49.21 - $64.19 $92,514 - $120,677	-1,880 Reduced 0.66%	284,845 $18.3 Million
Q3 2019 Nov 04, 2019	BUY	$42.77 - $50.71 $459,349 - $544,625	10,740 Added 3.89%	286,725 $14.5 Million
Q2 2019 Jul 31, 2019	BUY	$44.62 - $49.34 $1.41 Million - $1.56 Million	31,615 Added 12.94%	275,985 $12.5 Million
Q1 2019 May 01, 2019	BUY	$45.12 - $53.8 $1.2 Million - $1.43 Million	26,575 Added 12.2%	244,370 $11.7 Million
Q4 2018 Jan 31, 2019	SELL	$48.76 - $63.23 $22,429 - $29,085	-460 Reduced 0.21%	217,795 $11.3 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $169,709 - $191,418	3,075 Added 1.43%	218,255 $13.5 Million
Q2 2018 Aug 02, 2018	BUY	$50.53 - $62.98 $699,335 - $871,643	13,840 Added 6.87%	215,180 $11.9 Million
Q1 2018 Apr 30, 2018	BUY	$59.92 - $68.98 $117,742 - $135,545	1,965 Added 0.99%	201,340 $12.7 Million
Q4 2017 Jan 31, 2018	SELL	$59.94 - $65.35 $285,913 - $311,719	-4,770 Reduced 2.34%	199,375 $12.2 Million
Q3 2017 Oct 31, 2017	BUY	$55.23 - $63.74 $11.3 Million - $13 Million	204,145	204,145 $13 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kornitzer Capital Management Inc , based on Form 13F filings with the SEC.

News

Stay updated on Kornitzer Capital Management Inc with notifications on news.

Account

Kornitzer Capital Management Inc Bristol Myers Squibb CO Transaction History